Skip to main content
. 2010 Oct 25;10:581. doi: 10.1186/1471-2407-10-581

Table 4.

Change in FACT-F score

QW EDS Difference
(n = 374) (n = 378) (QW - EDS)
Baseline FACT-F score
 Patients included in the analysisa 330 337
 Mean (SD) 29.7 (12.4) 29.9 (12.4)
Change in FACT-F score from baseline to Week 13
 Patients included in the analysisb 256 268
 Least squares mean (95% CI) c 1.8 (0.5, 3.1) 2.5 (1.2, 3.7) -0.7 (-2.3, 0.9)
≥3-point increase in FACT-F score from baseline
 Patients included in the analysisa 330 337
 Through Week 13, n (%) 111 (34) 132 (39)
 Through the end of treatment, n (%) 155 (47) 173 (51)

aPatients missing a valid baseline and post-baseline FACT-F score were omitted from the analysis

bPatients missing a valid baseline and Week 13 FACT-F score were omitted from the analysis

cThe least squares means and CIs were computed from an ANOVA model after adjusting for the stratification factors at randomization (chemotherapy cycle length, screening hemoglobin, and tumor type), and baseline FACT-F score.

FACT-F = Functional Assessment of Cancer Therapy-Fatigue; QW = once weekly; EDS = extended dosing schedule; SD = standard deviation; CI = confidence interval; ANOVA = analysis of variance